Galantamina wynn

Overdose

Symptoms

Signs and symptoms of significant overdosing of Galantamina Wynn are predicted to be similar to those of overdosing of other cholinomimetics. These effects generally involve the central nervous system, the parasympathetic nervous system, and the neuromuscular junction. In addition to muscle weakness or fasciculations, some or all of the signs of a cholinergic crisis may develop: severe nausea, vomiting, gastro-intestinal cramping, salivation, lacrimation, urination, defecation, sweating, bradycardia, hypotension, collapse and convulsions. Increasing muscle weakness together with tracheal hypersecretions and bronchospasm, may lead to vital airway compromise.

There have been post-marketing reports of Torsade de Pointes, QT prolongation, bradycardia, ventricular tachycardia and brief loss of consciousness in association with an inadvertent overdoses of Galantamina Wynn. In one case where the dose was known, eight 4 mg tablets (32 mg total) were ingested on a single day.

Two additional cases of accidental ingestion of 32 mg (nausea, vomiting, and dry mouth; nausea, vomiting, and substernal chest pain) and one of 40 mg (vomiting) resulted in brief hospitalisations for observation with full recovery. One patient, who was prescribed 24 mg/day and had a history of hallucinations over the previous two years, mistakenly received 24 mg twice daily for 34 days and developed hallucinations requiring hospitalisation. Another patient, who was prescribed 16 mg/day of oral solution, inadvertently ingested 160 mg (40 ml) and experienced sweating, vomiting, bradycardia, and near-syncope one hour later, which necessitated hospital treatment. His symptoms resolved within 24 hours.

Treatment

As in any case of overdose, general supportive measures should be used. In severe cases, anticholinergics such as atropine can be used as a general antidote for cholinomimetics. An initial dose of 0.5 to 1.0 mg intravenously is recommended, with subsequent doses based on the clinical response.

Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control centre to determine the latest recommendations for the management of an overdose.

Contraindications

Because no data are available on the use of Galantamina Wynn in patients with severe hepatic impairment (Child-Pugh score greater than 9) and creatinine clearance less than 9 ml/min, Galantamina Wynn is contraindicated in these populations. Galantamina Wynn is contraindicated in patients who have both significant renal and hepatic dysfunction.

Incompatibilities

Not applicable.

Pharmaceutical form

Undesirable effects

The table below reflects data obtained with Galantamina Wynn in eight placebo-controlled, double-blind clinical trials (N=6,502), five open-label clinical trials (N=1,454), and from post marketing spontaneous reports. The most commonly reported adverse reactions were nausea (21%) and vomiting (11%). They occurred mainly during titration periods, lasted less than a week in most cases and the majority of patients had one episode. Prescription of anti-emetics and ensuring adequate fluid intake may be useful in these instances.

Frequency estimate: Very common (> 1/10), common (> 1/100 to < 1/10), uncommon (> 1/1,000 to < 1/100), rare (> 1/10,000 to <1/1,000) and very rare (< 1/10,000).

* Class-related effects reported with acetylcholinesterase-inhibitor antidementia drugs include convulsions/seizures

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard

Preclinical safety data

Nonclinical data suggest no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.

Reproduction toxicity studies showed a slight delay in development in rats and rabbits, at doses that are below the threshold of toxicity in the pregnant females.

Therapeutic indications

Galantamina Wynn is indicated for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type.

Pharmacotherapeutic group

Pharmacodynamic properties

Pharmacotherapeutic group: Antidementia drugs; ATC-code: N06DA04.

Mechanism of action

Galantamina Wynn, a tertiary alkaloid is a selective, competitive and reversible inhibitor of acetylcholinesterase. In addition, Galantamina Wynn enhances the intrinsic action of acetylcholine on nicotinic receptors, probably through binding to an allosteric site of the receptor. As a consequence, an increased activity in the cholinergic system associated with improved cognitive function can be achieved in patients with dementia of the Alzheimer type.

Clinical studies

The dosages of Galantamina Wynn effective in placebo-controlled clinical trials with a duration of 5 to 6 months were 16, 24 and 32 mg/day. Of these doses 16 and 24 mg/day were determined to have the best benefit/risk relationship and are the recommended maintenance doses. The efficacy of Galantamina Wynn has been shown using outcome measures which evaluate the three major symptom complexes of the disease and a global scale: the ADAS-Cog (a performance based measure of cognition), DAD and ADCS-ADL-Inventory (measurements of basic and instrumental Activities of Daily Living), the Neuropsychiatric Inventory (a scale that measures behavioural disturbances) and the CIBIC-plus (a global assessment by an independent physician based on a clinical interview with the patient and caregiver).

Composite responder analysis based on at least 4 points improvement in ADAS-Cog/11 compared to baseline and CIBIC-plus unchanged + improved (1-4), and DAD/ADL score unchanged + improved. See Table below.

Vascular dementia or Alzheimer's disease with cerebrovascular disease

The results of a 26-week double-blind placebo-controlled trial, in which patients with vascular dementia and patients with Alzheimer's disease and concomitant cerebrovascular disease (“mixed dementia”) were included, indicate that the symptomatic effect of Galantamina Wynn is maintained in patients with Alzheimer's disease and concomitant cerebrovascular disease. In a post-hoc subgroup analysis, no statistically significant effect was observed in the subgroup of patients with vascular dementia alone.

In a second 26-week placebo-controlled trial in patients with probable vascular dementia, no clinical benefit of Galantamina Wynn treatment was demonstrated.

Pharmacokinetic properties

Galantamina Wynn is an alkalinic compound with one ionisation constant (pKa 8.2). It is slightly lipophilic and has a partition coefficient (Log P) between n-octanol/buffer solution (pH 12) of 1.09. The solubility in water (pH 6) is 31 mg/ml. Galantamina Wynn has three chiral centres, the S, R, S-form is the naturally occurring form. Galantamina Wynn is partially metabolised by various cytochromes, mainly CYP2D6 and CYP3A4. Some of the metabolites formed during the degradation of Galantamina Wynn have been shown to be active in vitro but are of no importance in vivo.

Absorption

The absorption is rapid, with a tmax of about 1 hour after both tablets and oral solution. The absolute bioavailability of Galantamina Wynn is high, 88.5 ± 5.4%. The presence of food delays the rate of absorption and reduces Cmax by about 25%, without affecting the extent of absorption (AUC).

Distribution

The mean volume of distribution is 175 L. Plasma protein binding is low, 18%.

Biotransformation

Up to 75% of Galantamina Wynn dosed is eliminated via metabolism. In vitro studies indicate that CYP2D6 is involved in the formation of O-desmethylGalantamina Wynn and CYP3A4 is involved in the formation of N-oxide-Galantamina Wynn. The levels of excretion of total radioactivity in urine and faeces were not different between poor and extensive CYP2D6 metabolisers. In plasma from poor and extensive metabolisers, unchanged Galantamina Wynn and its glucuronide accounted for most of the sample radioactivity. None of the active metabolites of Galantamina Wynn (norGalantamina Wynn, O-desmethylGalantamina Wynn and O-desmethyl-norGalantamina Wynn) could be detected in their unconjugated form in plasma from poor and extensive metabolisers after single dosing. NorGalantamina Wynn was detectable in plasma from patients after multiple dosing, but did not represent more than 10% of the Galantamina Wynn levels. In vitro studies indicated that the inhibition potential of Galantamina Wynn with respect to the major forms of human cytochrome P450 is very low.

Elimination

Galantamina Wynn plasma concentration declines bi-exponentially, with a terminal half-life in the order of 7-8 h in healthy subjects. Typical oral clearance in the target population is about 200 ml/min with intersubject variability of 30% as derived from the population analysis. Seven days after a single oral dose of 4 mg ³H-Galantamina Wynn, 90-97% of the radioactivity is recovered in urine and 2.2 - 6.3% in faeces. After intravenous infusion and oral administration, 18-22% of the dose was excreted as unchanged Galantamina Wynn in the urine in 24 hours, with a renal clearance of 68.4 ± 22 ml/min, which represents 20-25% of the total plasma clearance.

Dose-linearity

After repeated oral dosing of 12 and 16 mg Galantamina Wynn twice daily as tablets, mean trough and peak plasma concentrations fluctuated between 29 - 97 ng/ml and 42 - 137 ng/ml. The pharmacokinetics of Galantamina Wynn are linear in the dose range of 4 - 16 mg twice daily. In patients taking 12 or 16 mg twice daily, no accumulation of Galantamina Wynn was observed between months 2 and 6.

Characteristics in patients with Alzheimer's disease

Data from clinical trials in patients indicate that the plasma concentrations of Galantamina Wynn in patients with Alzheimer's disease are 30-40% higher than in healthy young subjects. Based upon the population pharmacokinetic analysis, clearance in female subjects is 20% lower as compared to males. No major effects of age per se or race are found on the Galantamina Wynn clearance. The Galantamina Wynn clearance in poor metabolisers of CYP2D6 is about 25% lower than in extensive metabolisers, but no bimodality in the population is observed. Therefore, the metabolic status of the patient is not considered to be of clinical relevance in the overall population.

Special populations

Renal impairment

Elimination of Galantamina Wynn decreases with decreasing creatinine clearance as observed in a study with renally impaired subjects. Compared to Alzheimer patients, peak and trough plasma concentrations are not increased in patients with a creatinine clearance of >9 ml/min. Therefore, no increase in adverse events is expected and no dosage adjustments are needed.

Hepatic impairment

The pharmacokinetics of Galantamina Wynn in subjects with mild hepatic impairment (Child-Pugh score of 5-6) were comparable to those in healthy subjects. In patients with moderate hepatic impairment (Child-Pugh score of 7-9), AUC and half-life of Galantamina Wynn were increased by about 30%.

Pharmacokinetic / pharmacodynamic relationship

No apparent correlation between average plasma concentrations and efficacy parameters (i.e. change in ADAS-Cog11 and CIBIC-plus at Month 6) were observed in the large Phase III trials with a dose-regimen of 12 and 16 mg twice daily.

Plasma concentrations in patients experiencing syncope were within the same range as in the other patients at the same dose.

The occurrence of nausea is shown to correlate with higher peak plasma concentrations.

Name of the medicinal product

Qualitative and quantitative composition

Special warnings and precautions for use

Types of dementia

Galantamina Wynn is indicated for a patient with mild to moderately severe dementia of the Alzheimer type. The benefit of Galantamina Wynn in patients with other types of dementia or other types of memory impairment has not been demonstrated. In 2 clinical trials of two years duration in individuals with so called mild cognitive impairment (milder types of memory impairment not fulfilling the criteria of Alzheimer's dementia), Galantamina Wynn therapy failed to demonstrate any benefit either in slowing cognitive decline or reducing the clinical conversion to dementia. The mortality rate in the Galantamina Wynn group was significantly higher than in the placebo group, 14/1026 (1.4%) patients on Galantamina Wynn and 3 /1022 (0.3%) patients on placebo. The deaths were due to various causes. About half of the Galantamina Wynn deaths appeared to result from various vascular causes (myocardial infarction, stroke, and sudden death). The relevance of this finding for the treatment of patients with Alzheimer's dementia is unknown.

No increased mortality in the Galantamina Wynn group was observed in a long term, randomized, placebo controlled study in 2045 patients with mild to moderate Alzheimer´s disease. The mortality rate in the placebo group was significantly higher than in the Galantamina Wynn group. There were 56/1021 (5.5%) deaths in patients on placebo and 33/1024 (3.2%) deaths in patients on Galantamina Wynn (hazard ratio and 95% confidence intervals of 0.58 [0.37 , 0.89]; p=0.011).

A diagnosis of Alzheimer's dementia should be made according to current guidelines by an experienced physician. Therapy with Galantamina Wynn should occur under the supervision of a physician and should only be initiated if a caregiver is available who will regularly monitor medicinal product intake by the patient.

Serious skin reactions

Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving Galantamina Wynn. It is recommended that patients be informed about the signs of serious skin reactions, and that use of Galantamina Wynn be discontinued at the first appearance of skin rash.

Weight monitoring

Patients with Alzheimer's disease lose weight. Treatment with cholinesterase inhibitors, including Galantamina Wynn, has been associated with weight loss in these patients. During therapy, patient's weight should be monitored.

Conditions requiring caution

As with other cholinomimetics, Galantamina Wynn should be given with caution in the following conditions:

Cardiac disorders:

Because of their pharmacological action, cholinomimetics may have vagotonic effects on heart rate (e.g. bradycardia). The potential for this action may be particularly important to patients with 'sick sinus syndrome' or other supraventricular cardiac conduction disturbances or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers or for patients with an uncorrected electrolyte disturbance (e.g. hyperkalaemia, hypokalaemia).

Caution should therefore be exercised when administering Galantamina Wynn to patients with cardiovascular diseases, e.g. immediate post- myocardial infarction period, new-onset atrial fibrillation, second degree heart block or greater, unstable angina pectoris, or congestive heart failure, especially NYHA group III - IV.

In a pooled analysis of placebo-controlled studies in patients with Alzheimer dementia treated with Galantamina Wynn an increased incidence of certain cardiovascular adverse events were observed.

Gastrointestinal disorders:

Patients at increased risk of developing peptic ulcers, e.g. those with a history of ulcer disease or those predisposed to these conditions, including those receiving concurrent non-steroidal anti-inflammatory drugs (NSAIDS),should be monitored for symptoms. The use of Galantamina Wynn is not recommended in patients with gastro-intestinal obstruction or recovering from gastro-intestinal surgery.

Nervous system disorders:

Seizures have been reported with Galantamina Wynn. Seizure activity may also be a manifestation of Alzheimer's disease. In rare cases an increase in cholinergic tone may worsen Parkinsonian symptoms. In a pooled analysis of placebo-controlled studies in patients with Alzheimer's dementia treated with Galantamina Wynn cerebrovascular events were uncommonly observed. This should be considered when administering Galantamina Wynn to patients with cerebrovascular disease.

Respiratory, thoracic and mediastinal disorders:

Cholinomimetics should be prescribed with care for patients with a history of severe asthma or obstructive pulmonary disease or active pulmonary infections (e.g. pneumonia).

Renal and urinary disorders:

The use of Galantamina Wynn is not recommended in patients with urinary outflow obstruction or recovering from bladder surgery.

Surgical and medical procedures: Galantamina Wynn, as a cholinomimetic is likely to exaggerate succinylcholinetype muscle relaxation during anaesthesia, especially in cases of pseudocholinesterase deficiency.

Excipient of Galantamina Wynn 4 mg/ml oral solution:

This product contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

Methyl-/Propyl-para-hydroxybenzoate may cause allergic reactions (possibly delayed).

Effects on ability to drive and use machines

Galantamina Wynn has minor to moderate influence on the ability to drive and use machines. Symptoms include dizziness and somnolence, especially during the first weeks after initiation of treatment.

Dosage (Posology) and method of administration

Posology

Adults/Elderly

Before start of treatment

The diagnosis of probable Alzheimer type of dementia should be adequately confirmed according to current clinical guidelines.

Starting dose

The recommended starting dose is 8 mg/day (4 mg twice a day) for four weeks.

Maintenance dose

- The tolerance and dosing of Galantamina Wynn should be reassessed on a regular basis, preferably within three months after start of treatment. Thereafter, the clinical benefit of Galantamina Wynn and the patient's tolerance of treatment should be reassessed on a regular basis according to current clinical guidelines. Maintenance treatment can be continued for as long as therapeutic benefit is favourable and the patient tolerates treatment with Galantamina Wynn. Discontinuation of Galantamina Wynn should be considered when evidence of a therapeutic effect is no longer present or if the patient does not tolerate treatment.

The initial maintenance dose is 16 mg/day (8 mg twice a day) and patients should be maintained on 16 mg/day for at least 4 weeks.

An increase to the maintenance dose of 24 mg/day (12 mg twice a day) should be considered on an individual basis after appropriate assessment including evaluation of clinical benefit and tolerability.

- In individual patients not showing an increased response or not tolerating 24 mg/day, a dose reduction to 16 mg/day should be considered.

Treatment withdrawal

- There is no rebound effect after abrupt discontinuation of treatment (e.g. in preparation for surgery).

Renal impairment

Galantamina Wynn plasma concentrations may be increased in patients with moderate to severe renal impairment.

For patients with a creatinine clearance >9 ml/min, no dosage adjustment is required.

The use of Galantamina Wynn is contraindicated in patients with creatinine clearance less than 9 ml/min.

Hepatic impairment

Galantamina Wynn plasma concentrations may be increased in patients with moderate to severe hepatic impairment.

In patients with moderately impaired hepatic function (Child-Pugh score 7-9), based on pharmacokinetic modelling, it is recommended that dosing should begin with 4 mg once daily, preferably taken in the morning, for at least one week. Thereafter, patients should proceed with 4 mg twice daily. for at least 4 weeks. In these patients, daily doses should not exceed 8 mg twice daily.

In patients with severe hepatic impairment (Child-Pugh score greater than 9), the use of Galantamina Wynn is contraindicated. No dosage adjustment is required for patients with mild hepatic impairment.

Concomitant treatment

In patients treated with potent CYP2D6 or CYP3A4 inhibitors dose reductions can be considered.

Paediatric population

There is no relevant use of Galantamina Wynn in the paediatric population.

Method of administration

Galantamina Wynn oral solution should be administered orally twice a day, preferably with morning and evening meals. Ensure adequate fluid intake during treatment.

Special precautions for disposal and other handling

To open the bottle and use the pipette:

The bottle comes with a child-proof cap, and should be opened as follows:

- Push the plastic screw cap down while turning it counter clockwise.

- Remove the unscrewed cap.

Insert the pipette into the bottle.

While holding the bottom ring, pull the top ring up to the mark corresponding to the number of millilitres you need to give.

Holding the bottom ring, remove the entire pipette from the bottle.

Empty the pipette directly into the mouth or into any non-alcoholic drink by sliding the upper ring down and drink it immediately.

Close the bottle.

Rinse the pipette with some water.